Exact Sciences (NASDAQ:EXAS), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, will present its case before an FDA panel of experts on March 27 to argue for approval of its new stool-based DNA screening test Cologuard for colorectal cancer ("CRC"). Currently Laboratory Corporation of America or LabCorp's (NYSE:LH) ColoSure is the only fecal DNA test for colorectal cancer available in the United States. If Cologuard...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|